Literature DB >> 19945427

PEDF regulates osteoclasts via osteoprotegerin and RANKL.

Toru Akiyama1, Crispin R Dass, Yusuke Shinoda, Hirotaka Kawano, Sakae Tanaka, Peter F M Choong.   

Abstract

Bone homeostasis is maintained through a balance between bone formation and resorption. Bone resorption is mainly carried out by a specific type of cell called the osteoclast (OCL). Previously, expression of pigment epithelium-derived factor (PEDF), the most potent endogenous inhibitor of angiogenesis, has been demonstrated in bone tissue and it known to induce differentiation in osteoblastic cells. Furthermore, therapeutic effects of PEDF on osteosarcoma, a prevalent primary bone tumor, with inhibition of bone destruction has been shown. Thus, PEDF is possibly involved in bone homeostasis as an inhibitor of bone resorption. To address this involvement, we studied the effect of PEDF on OCL function. OCL differentiation, RANKL-mediated survival and bone resorption activity were inhibited by PEDF in a dose-dependent manner. PEDF upregulated osteoprotegerin (OPG), which naturally blocks OCL maturation, in primary osteoblasts and OCL precursor cells. These results suggest that PEDF inhibits OCL function via regulating OPG expression, and thereby contributes to the maintenance of bone homeostasis. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945427     DOI: 10.1016/j.bbrc.2009.11.139

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta.

Authors:  Jutta Becker; Oliver Semler; Christian Gilissen; Yun Li; Hanno Jörn Bolz; Cecilia Giunta; Carsten Bergmann; Marianne Rohrbach; Friederike Koerber; Katharina Zimmermann; Petra de Vries; Brunhilde Wirth; Eckhard Schoenau; Bernd Wollnik; Joris A Veltman; Alexander Hoischen; Christian Netzer
Journal:  Am J Hum Genet       Date:  2011-02-25       Impact factor: 11.025

2.  Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.

Authors:  Xin Li; Wen Ling; Sharmin Khan; Shmuel Yaccoby
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

3.  Pigment epithelium-derived factor restoration increases bone mass and improves bone plasticity in a model of osteogenesis imperfecta type VI via Wnt3a blockade.

Authors:  Glenn S Belinsky; Bharath Sreekumar; Jillian W Andrejecsk; W Mark Saltzman; Jingjing Gong; Raimund I Herzog; Samantha Lin; Valerie Horsley; Thomas O Carpenter; Chuhan Chung
Journal:  FASEB J       Date:  2016-04-28       Impact factor: 5.191

4.  A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor.

Authors:  Charles R Farber; Adi Reich; Aileen M Barnes; Patricia Becerra; Frank Rauch; Wayne A Cabral; Alison Bae; Aaron Quinlan; Francis H Glorieux; Thomas L Clemens; Joan C Marini
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

Review 5.  Osteogenesis imperfecta.

Authors:  Antonella Forlino; Joan C Marini
Journal:  Lancet       Date:  2015-11-03       Impact factor: 79.321

6.  Pigment epithelium-derived factor is retinal ganglion cell neuroprotective and axogenic after optic nerve crush injury.

Authors:  Vasanthy Vigneswara; Martin Berry; Ann Logan; Zubair Ahmed
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-12       Impact factor: 4.799

Review 7.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Authors:  Anne-Priscille Trouvin; Vincent Goëb
Journal:  Clin Interv Aging       Date:  2010-11-19       Impact factor: 4.458

8.  Mutations in SERPINF1 cause osteogenesis imperfecta type VI.

Authors:  Erica P Homan; Frank Rauch; Ingo Grafe; Caressa Lietman; Jennifer A Doll; Brian Dawson; Terry Bertin; Dobrawa Napierala; Roy Morello; Richard Gibbs; Lisa White; Rika Miki; Daniel H Cohn; Susan Crawford; Rose Travers; Francis H Glorieux; Brendan Lee
Journal:  J Bone Miner Res       Date:  2011-12       Impact factor: 6.741

Review 9.  Cell and molecular biology underpinning the effects of PEDF on cancers in general and osteosarcoma in particular.

Authors:  Vijay Chandolu; Crispin R Dass
Journal:  J Biomed Biotechnol       Date:  2012-05-28

Review 10.  The emerging role of PEDF in stem cell biology.

Authors:  Mina Elahy; Swati Baindur-Hudson; Crispin R Dass
Journal:  J Biomed Biotechnol       Date:  2012-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.